Novel Drug Regimen for the Treatment of Alzheimer's Disease
- Detailed Technology Description
- Executive Summary Alzheimers’ disease (AD), the leading cause of dementia is a very complex disorder with a variety of molecular and cellular pathological alterations. For many patients, the current pharmacological treatment proves ineffective. Current research suggests that changes in the polyamine levels are a possible factor in causing Alzheimer’s disease and other mental and neurodegenerative disorders. MSU researchers are proposing a novel drug regimen for the treatment of AD based on an approved cancer pharmaceutical that affects the polyamine system, possibly alleviating and slowing down the progression of AD. Description of Technology The intake of an already established pharmaceutical for cancer treatment is suggested to be used alone or synergistically in combination with Vitamin E. MSU researchers have identified that this drug irreversibly inhibits the activity of an enzyme in the polyamine pathway which may be linked to the onset and progression of AD. Key BenefitsGood compliance of drugLow cytotoxicity and low side effects of drug Good blood-brain barrier permeability of drug ApplicationsTreatment of Alzheimer’s disease and other neurodegenerative disorders Patent Status: Under review Licensing Rights Available Full licensing rights available Inventors: Andre Bachmann Tech ID: TEC2016-0079 Alternative contact due to temporary leave: Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.
- *Abstract
-
None
- *Principal Investigator
-
Name: Andre Bachmann, Professor
Department: Pediatrics & Human Development
- Country/Region
- USA
For more information, please click Here
